Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent

BACKGROUND: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy (MG) is a known adverse progn...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Exp Hematol Oncol
Главные авторы: Mondello, Patrizia, Pitini, Vincenzo, Barresi, Valeria, Brea, Elliott Joseph, Di Mirto, Cristian, Arrigo, Carmela, Cuzzocrea, Salvatore, Mian, Michael
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2016
Предметы:
Case Report
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4702294/
https://ncbi.nlm.nih.gov/pubmed/26740908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-015-0030-1
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы